Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma

Immunotherapy

Volumn 5, Issue 5, 2013, Pages 489-495

  Muselaers, Stijn ^a   Mulders, Peter ^a   Oosterwijk, Egbert ^a   Oyen, Wim ^a   Boerman, Otto ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

carbonic anhydrase IX; G250; girentuximab; molecular imaging; renal cell carcinoma

Indexed keywords

CARBONATE DEHYDRATASE IX; DIURETIC AGENT; FLUORODEOXYGLUCOSE F 18; GIRENTUXIMAB; INDIUM 111; IODINE 124; IODINE 131; LUTETIUM 177; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; YTTRIUM 90;

CANCER SURVIVAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG DOSE ESCALATION; FALSE POSITIVE RESULT; HUMAN; IMMUNOGENICITY; KIDNEY CARCINOMA; MOLECULAR IMAGING; NEPHRECTOMY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANTIBODIES, MONOCLONAL; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; HUMANS; KIDNEY NEOPLASMS; MOLECULAR IMAGING; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84877253881     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.36     Document Type: Review

References (68)

1. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 281(17), 1628-1631 (1999).
2. Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat. Rev. Urol. 7(5), 245-257 (2010).
3. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int. J. Cancer 83(1), 18-29 (1999).
4. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol. Clin. North Am. 30(4), 843-852 (2003).
5. Nabi G, Cleves A, Shelley M. Surgical management of localised renal cell carcinoma. Cochrane Database Syst. Rev. 3, CD006579 (2010).
6. Volpe A, Mattar K, Finelli A et al. Contemporary results of percutaneous biopsy of 100 small renal masses: a single center experience. J. Urol. 180(6), 2333-2337 (2008).
7. Schmidbauer J, Remzi M, Memarsadeghi M et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur. Urol. 53(5), 1003-1011 (2008).
8. Yagoda A, Petrylak D, Thompson S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am. 20(2), 303-321 (1993).
9. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J. Urol. 163(2), 408-417 (2000).
10. Gore ME, Griffin CL, Hancock B et al. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 375(9715), 641-648 (2010).
11. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007).
12. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010).
13. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011).
14. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007).
15. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18), 4256-4265 (2010).
16. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
17. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet 372(9637), 449-456 (2008).
18. Escudier B, Bellmunt J, Negrier S et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 28(13), 2144-2150 (2010).
19. Rini BI, Halabi S, Rosenberg JE et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol. 28(13), 2137-2143 (2010).
20. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr. Drug Metab. 10(5), 470-481 (2009).
21. Desar IM, Mulder SF, Stillebroer AB et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol. 48(6), 927-931 (2009).
22. Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. [Positron emission tomography in diagnosis of renal cell carcinoma]. Urologe A 35(2), 146-150 (1996).
23. Wang HY, Ding HJ, Chen JH et al. Meta-analysis of the diagnostic performance of 18F-FDG-PET and PET/CT in renal cell carcinoma. Cancer Imaging 12, 464-474 (2012).
24. Lawrentschuk N, Poon AM, Scott AM. Fluorine-18 fluorothymidine: a new positron emission radioisotope for renal tumors. Clin. Nucl. Med. 31(12), 788-789 (2006).
25. Lawrentschuk N, Poon AM, Foo SS et al. Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 96(4), 540-546 (2005).
26. Oyama N, Okazawa H, Kusukawa N et al. 11C-acetate PET imaging for renal cell carcinoma. Eur. J. Nucl. Med. Mol. Imaging 36(3), 422-427 (2009).
27. Oosterwijk E, Ruiter DJ, Hoedemaeker PJ et al. Monoclonal antibody G250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int. J. Cancer 38(4), 489-494 (1986).
28. Surfus JE, Hank JA, Oosterwijk E et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J. Immunother. Emphasis Tumor Immunol. 19(3), 184-191 (1996).
29. Pastorek J, Pastorekova S, Callebaut I et al. Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 9(10), 2877-2888 (1994).
30. Opavsky R, Pastorekova S, Zelnik V et al. Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 33(3), 480-487 (1996).
31. Genega EM, Ghebremichael M, Najarian R et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am. J. Clin. Pathol. 134(6), 873-879 (2010).
32. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9(2), 802-811 (2003).
33. Leibovich BC, Sheinin Y, Lohse CM et al. Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. J. Clin. Oncol. 25(30), 4757-4764 (2007).
34. Bui MH, Visapaa H, Seligson D et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J. Urol. 171(6 Pt 1), 2461-2466 (2004).
35. Patard JJ, Fergelot P, Karakiewicz PI et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int. J. Cancer 123(2), 395-400 (2008).
36. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 100(3), 556-560 (2007).
37. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin. Cancer Res. 11(10), 3714-3721 (2005).
38. Davis ID, Wiseman GA, Lee FT et al. A Phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun. 7, 13 (2007).
39. Bleumer I, Knuth A, Oosterwijk E et al. A Phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br. J. Cancer 90(5), 985-990 (2004).
40. Steffens MG, Boerman OC, Oosterwijk-Wakka JC et al. Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J. Clin. Oncol. 15(4), 1529-1537 (1997).
41. Brouwers AH, Dorr U, Lang O et al. 131I-cG250 monoclonal antibody immunoscintigraphy versus [18F]FDG-PET imaging in patients with metastatic renal cell carcinoma: a comparative study. Nucl. Med. Commun. 23(3), 229-236 (2002).
42. Brouwers AH, Buijs WC, Oosterwijk E et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. Clin. Cancer Res. 9(10 Pt 2), S3953-S3960 (2003).
43. Muselaers CH, Boerman OC, Oosterwijk E, Langenhuijsen JF, Oyen WJ, Mulders PF. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. Eur. Urol. pii: S0302- 2838(13)00134-6 (2013).
44. Divgi CR, Pandit-Taskar N, Jungbluth AA et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a Phase I trial. Lancet Oncol. 8(4), 304-310 (2007).
45. Pryma DA, O'Donoghue JA, Humm JL et al. Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250. J. Nucl. Med. 52(4), 535-540 (2011).
46. Divgi CR, Uzzo RG, Gatsonis C et al. Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial. J. Clin. Oncol. 31(2), 187-194 (2012).
47. Povoski SP, Hall NC, Murrey DA Jr et al. Multimodal imaging and detection strategy with 124I-labeled chimeric monoclonal antibody cG250 for accurate localization and confirmation of extent of disease during laparoscopic and open surgical resection of clear cell renal cell carcinoma. Surg. Innov. 20(1), 59-69 (2013).
48. Brouwers A, Verel I, Van Eerd J et al. PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. Cancer Biother. Radiopharm. 19(2), 155-163 (2004).
49. Muselaers CHJ, Stillebroer AB, Boers-Sonderen MJ et al. Sorafenib reduces the tumor uptake of indium-111-girentuximab in clear cell renal cell carcinoma patients. Eur. J. Nucl. Med. Mol. Imaging 39(Suppl. 2), S188- S189 (2012).
50. Gordon LI, Witzig T, Molina A et al. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma. Clin. Lymphoma 5(2), 98-101 (2004).
51. Wiseman GA, Gordon LI, Multani PS et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non- Hodgkin lymphoma and mild thrombocytopenia: a Phase II multicenter trial. Blood 99(12), 4336-4342 (2002).
52. Witzig TE, Flinn IW, Gordon LI et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J. Clin. Oncol. 20(15), 3262-3269 (2002).
53. Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90- labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J. Clin. Oncol. 20(10), 2453-2463 (2002).
54. Divgi CR, Bander NH, Scott AM et al. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin. Cancer Res. 4(11), 2729-2739 (1998).
55. Steffens MG, Boerman OC, De Mulder PH et al. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin. Cancer Res. 5(Suppl. 10), S3268-S3274 (1999).
56. Divgi CR, O'Donoghue JA, Welt S et al. Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J. Nucl. Med. 45(8), 1412-1421 (2004).
57. Brouwers AH, Mulders PF, De Mulder PH et al. Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. J. Clin. Oncol. 23(27), 6540-6548 (2005).
58. Brouwers AH, Buijs WC, Mulders PF et al. Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. Clin. Cancer Res. 11(19 Pt 2), S7178-S7186 (2005).
59. Brouwers AH, van Eerd JE, Frielink C et al. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J. Nucl. Med. 45(2), 327-337 (2004).
60. Stillebroer AB, Boerman OC, Desar IM et al. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. Eur. Urol. pii: S0302-2838(12)00959-1 (2012).
61. Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA. Bone marrow dosimetry using 124I-PET. J. Nucl. Med. 53(4), 615-621 (2012).
62. Stillebroer AB, Zegers CM, Boerman OC et al. Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. J. Nucl. Med. 53(1), 82-89 (2012).
63. Evaluate the utility of 124I-cG250 for the early detection of response to therapy in patients with metastatic renal cell carcinoma. http:// clinicaltrials.gov/show/NCT01582204
64. Effect of sorafenib on ccRCC uptake of radiolabeled bevacizumab or cG250. http://clinicaltrials.gov/show/NCT00602862
65. Monoclonal antibody therapy (Rencarex®) in treating patients who have undergone surgery for non-metastatic kidney cancer. http://clinicaltrials.gov/ show/NCT00087022
66. Phase III ARISER trial with RENCAREX® press release (Wilex AG, Munich, Germany). www.wilex.de/portfolio-english/rencarex/ overview-rencarex
67. Study of lutetium-177 labeled cG250 in patients with advanced renal cancer. http://clinicaltrials.gov/show/NCT00142415
68. Treatment of patients with advanced renal cancer with a radiolabeled antibody, yttrium-90 conjugated chimeric G250. http://clinicaltrials.gov/show/ NCT00199875